A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo
Sponsor: Incyte Corporation
This PHASE2 trial investigates Nonsegmental Vitiligo With Genital Involvement and is currently completed. Incyte Corporation leads this study, which shows 16 recorded versions since 2023 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE2
-
May 2025 — Aug 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barrie, Canada , Bordeaux, France , Calgary, Canada , Créteil, France , Fort Gratiot, United States , Fremont, United States , Los Angeles, United States , Mayfield, United States , Nice, France , Peterborough, Canada and 3 more locations